Blood Transfusion Diagnostics Market Overview
The Blood Transfusion Diagnostics Market is expanding as healthcare systems place greater emphasis on blood safety, accurate blood typing, infectious-disease screening, and compatibility testing. Rising surgical and trauma transfusion volumes, regulatory requirements for pathogen screening, blood-bank automation, and increasing adoption of molecular diagnostics are supporting demand for advanced transfusion diagnostic solutions.
According to the Market Research Future report updated July 22, 2026, the global Blood Transfusion Diagnostics Market was valued at USD 6.52 Billion in 2025 and is projected to grow from USD 6.96 Billion in 2026 to USD 12.49 Billion by 2035, registering a CAGR of 6.72% during 2025–2035. North America led the market with approximately 38% share in 2025, while Asia-Pacific is the fastest-growing region with an estimated CAGR of 8.4%. Consumables accounted for more than 62% of market revenue, Serology represented approximately USD 4.10 Billion in 2025, Disease Screening held 55% share, and Hospitals accounted for 45% of end-user revenue.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/1126
Key players driving innovation and competitiveness in the Blood Transfusion Diagnostics Market include:
Grifols
Roche
Abbott
Terumo
Ortho Clinical Diagnostics
Bio-Rad Laboratories
Beckman Coulter
Siemens Healthineers
Hologic
The Blood Transfusion Diagnostics Market is being driven by increasing surgical and trauma-related transfusion volumes, mandatory pathogen screening requirements, and growing awareness of blood safety. The transition from manual testing toward automated column-agglutination and solid-phase platforms is improving testing speed and reducing human error, while nucleic acid testing is gaining adoption for HIV, HBV, HCV, and other pathogen screening. Government-led blood safety programs and investments in blood-bank modernization are further supporting market expansion.
Market Segmentation: By product type, Consumables lead with more than 62% share, while Instruments are the fastest-growing category at a 7.8% CAGR. By technology, Serology remains dominant with approximately USD 4.10 Billion in 2025 revenue, while Nucleic Acid Testing is projected to grow at an 8.3% CAGR. By application, Disease Screening accounts for 55% share, while Blood Group Typing is projected to grow at a 7.4% CAGR. By end user, Hospitals lead with 45% share, while Diagnostic Laboratories generated approximately USD 2.48 Billion in 2025.
Significant opportunities are emerging from point-of-care blood-typing devices, AI-driven antibody identification, emerging-market blood-bank modernization, digital hemovigilance platforms, and pathogen-reduction technologies. The expansion of blood-bank infrastructure in Asia-Pacific, South Asia, and Africa is creating additional demand for screening, typing, and compatibility-testing systems, while cloud-connected platforms can support more efficient inventory management and transfusion safety.
Recent Developments and Market Trends:
Automation is transforming blood banks by replacing manual testing workflows with integrated robotic and digital diagnostic platforms.
Nucleic acid testing is gaining momentum as regulatory requirements increasingly emphasize individual-donor pathogen screening.
AI and machine-learning technologies are being explored for antibody identification, inventory optimization, and transfusion decision support.
Point-of-care blood-typing devices are creating new opportunities for emergency departments, remote clinics, military facilities, and decentralized healthcare settings.
Emerging-market investments in blood-bank modernization are expanding demand for automated instruments, reagents, molecular diagnostics, and digital blood-management systems.
Reasons to Buy the Report:
Gain detailed insights into the global Blood Transfusion Diagnostics Market size, growth rate, and forecast through 2035.
Understand the competitive landscape involving Grifols, Roche, Abbott, Terumo, Ortho Clinical Diagnostics, Bio-Rad Laboratories, and other leading companies.
Evaluate opportunities across product types, technologies, applications, end users, and regional markets.
Identify the impact of blood safety regulations, surgical volumes, automation, molecular diagnostics, and healthcare infrastructure investment on market growth.
Assess future investment opportunities associated with AI-enabled diagnostics, point-of-care testing, NAT platforms, and digital blood-bank management.
Future Outlook:
The Blood Transfusion Diagnostics Market is expected to reach USD 12.49 Billion by 2035, expanding at a CAGR of 6.72% during 2025–2035. Consumables are expected to remain the largest product category, supported by recurring demand for reagents, test cards, and NAT assay kits, while Instruments are positioned for faster growth at a 7.8% CAGR as hospitals and blood banks modernize aging manual systems. Serology will continue to represent the dominant technology, while Nucleic Acid Testing is expected to gain share at an 8.3% CAGR as pathogen-screening requirements expand. Disease Screening will remain the largest application at 55% share, while Blood Group Typing is projected to grow at 7.4% CAGR as extended antigen profiling and genotyping gain adoption. Hospitals will continue to lead the end-user market with 45% share. North America is expected to retain its leading position with 38% share, while Asia-Pacific will remain the fastest-growing region at an 8.4% CAGR, supported by blood-bank infrastructure development, increasing healthcare investment, and broader adoption of advanced transfusion diagnostics.
➤➤Explore Our Latest Related Reports:
